Information on this website is provided for informational purposes only and is not a substitute for professional medical advice.
An Lp(a) blood test measures Lipoprotein(a), a genetic "bad" cholesterol particle that significantly raises the risk for heart attack, stroke, and atherosclerosis (hardening of arteries), even with normal routine cholesterol levels.
It's often ordered for individuals with family histories of early heart disease or recurrent events, as levels are mainly inherited and don't change much with lifestyle.
The test helps assess hidden cardiovascular risks not caught by standard lipid panels, with high levels indicating greater risk.
Lp(a): A particle similar to LDL ("bad") cholesterol, but carries more cholesterol and promotes plaque buildup in arteries.
Genetic marker: Levels are primarily determined by your genes, making it a stable, lifelong risk factor.
To assess risk for heart attack, stroke, or peripheral artery disease.
For those with a strong family history of early heart disease or stroke.
If routine cholesterol tests are normal but cardiovascular risk seems high.
To understand unexplained heart issues or plaque buildup.
Results reported in nmol/L (number of particles):
Low < 100
Moderate 100 – 200
High 200 – 400
Very high > 400
A simple blood draw is taken from your arm.
Fasting (no food, smoking, or non-water drinks for 9-12 hours) may be required.
It's a one-time test for many, but your doctor might repeat it to confirm or monitor changes (e.g., after menopause).
Lp(a) testing identifies genetic risk for heart disease missed by standard tests, guiding proactive management for high-risk individuals.
Time to consider a vital new cholesterol test, Victor Chang Cardiac Research Institute
Ask a cardiologist: Do I need an Lp(a) cholesterol test?, video, Victor Chang Cardiac Research Institute
Lipoprotein (a): Levels & Testing, Cleveland Clinic
An ApoB (Apolipoprotein B) blood test measures the number of harmful, plaque-forming lipoprotein particles (LDL, VLDL) in your blood, serving as a superior, more direct marker for cardiovascular disease (CVD) risk than traditional LDL cholesterol testing.
Elevated levels indicate a higher risk of heart disease and stroke.
In Australia, Medicare does not cover ApoB blood tests.
What it Measures: ApoB is the primary protein component of all atherogenic (artery-clogging) lipoprotein particles. Because each particle contains exactly one ApoB molecule, this test directly counts these harmful particles.
Why it is Done: It provides a clearer picture of cardiovascular risk, particularly for people with high triglycerides, diabetes, or a family history of heart disease. It is also used to monitor the effectiveness of lipid-lowering treatments, such as statins.
Optimal Levels:
While results can vary, an optimal level in many contexts is considered to be below 0.8 g/L (or 80 mg/dL)
Levels above 100-110 mg/dL100 are generally considered high-risk.
Preparation: Fasting is often not strictly required, though it is best to check with the testing provider.
LDL-C (Conventional): Measures the total amount of cholesterol inside LDL particles.
ApoB (Advanced): Measures the actual number of particles.
The Difference: A person might have normal LDL cholesterol numbers, but if those particles are small and numerous, their ApoB will be high, indicating high risk.
If ApoB is high, lifestyle adjustments such as a heart-healthy (e.g., Mediterranean-style) diet and regular exercise may help, though medications like statins, ezetimibe, or PCSK9 inhibitors are often more effective for reduction.
Apolipoprotein B (APOB) Test, Cleveland Clinic
Testing for both Apolipoprotein B (ApoB) and Lipoprotein(a) [Lp(a)] is essential because they provide a complete picture of cardiovascular risk that standard cholesterol tests often miss. While routine tests measure the mass of cholesterol, these advanced markers measure the actual number and type of dangerous particles in the blood.
ApoB is considered a stronger predictor of cardiovascular risk than standard LDL-C because it measures the total number of all atherogenic (plaque-forming) particles, including LDL, VLDL, and IDL.
Precision: Because every "bad" cholesterol particle carries exactly one molecule of ApoB, the test provides an accurate particle count.
Predictive Power: In patients who have reached their target LDL-C levels, elevated ApoB can reveal "residual risk" for heart attacks and strokes.
Lp(a) is an independent, genetically determined risk factor that is not included in standard lipid panels.
Structural Danger: Lp(a) is an LDL-like particle with an added "sticky" protein called Apo(a), which makes it more likely to cause arterial blockages, inflammation, and blood clots.
Stability: Levels are inherited and remain virtually constant throughout life, meaning the test usually only needs to be performed once.
Risk Reclassification: Identifying high Lp(a) can reclassify up to 20–30% of patients from a "low" or "moderate" risk category to "high risk," significantly changing their treatment plan.
Using both tests together allows clinicians to perform precision risk assessment and calculate the exact contribution of Lp(a) to a patient’s total particle count.
Calculating Proportions: By measuring both in molar units (nmol/L), a doctor can determine what percentage of a patient's total ApoB particles are the higher-risk Lp(a) variant.
Aggressive Prevention: Since specific Lp(a)-lowering drugs are still in clinical trials, the primary management strategy for high Lp(a) is to aggressively lower the other modifiable particles (measured by ApoB) to mitigate the total risk.
Family Screening: A high result in either test—particularly Lp(a)—serves as a trigger for cascade screening, identifying high-risk parents, siblings, and children who may appear healthy but carry the same genetic predisposition.
In summary, the ApoB test identifies the quantity of atherogenic particles, while the Lp(a) test identifies a specific, high-risk genetic quality of those particles, both of which are critical for preventing premature heart disease.